Position in BBIO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$32,081,359
-$263,185 QoQ
Shares Held
432,014
-30.6% QoQ
Ownership
0.221%
of shares outstanding
% of Portfolio
6.70%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Catalio Capital Management, LP holds $360,864,886 across 31 Biotechnology names. BBIO ranks #2 (8.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
560,308 | $47,021,047 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
This page
|
432,014 | $32,081,359 | |
| 3 | ASND |
Ascendis Pharma A/S
|
129,111 | $29,531,559 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
1,043,670 | $24,380,131 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
409,031 | $21,564,114 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
1,037,984 | $19,617,897 | |
| 7 | SLNO |
Soleno Therapeutics Inc
|
577,808 | $19,345,011 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
850,797 | $17,824,197 |
All Filings in BBIO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $32,081,359 | 432,014 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $32,344,544 | 622,729 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $40,058,560 | 927,711 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $33,286,865 | 962,883 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $24,653,687 | 898,458 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||